CY1108544T1 - Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης - Google Patents

Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης

Info

Publication number
CY1108544T1
CY1108544T1 CY20081100762T CY081100762T CY1108544T1 CY 1108544 T1 CY1108544 T1 CY 1108544T1 CY 20081100762 T CY20081100762 T CY 20081100762T CY 081100762 T CY081100762 T CY 081100762T CY 1108544 T1 CY1108544 T1 CY 1108544T1
Authority
CY
Cyprus
Prior art keywords
methods
byrazol
products
compositions containing
containing composite
Prior art date
Application number
CY20081100762T
Other languages
English (en)
Inventor
Emma R Parmee
Yusheng Xiong
Jian Guo
Rui Liang
Linda Brockunier
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1108544T1 publication Critical patent/CY1108544T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Περιγράφονται πυραζόλια που φέρουν προσδεμένη ναφθυλο ομάδα. Οι ενώσεις είναι χρήσιμες για την αντιμέτωπιση του διαβήτη τύπου 2 και συναφών καταστάσεων. Περιλαμβάνονται επίσης και φαρμακευτικές συνθέσεις και μέθοδοι θεραπείας.
CY20081100762T 2004-06-04 2008-07-21 Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης CY1108544T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
EP05754758A EP1756064B1 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
CY1108544T1 true CY1108544T1 (el) 2014-04-09

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100762T CY1108544T1 (el) 2004-06-04 2008-07-21 Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης

Country Status (34)

Country Link
US (2) US7598285B2 (el)
EP (1) EP1756064B1 (el)
JP (2) JP4108739B2 (el)
CN (1) CN1964947A (el)
AR (2) AR049291A1 (el)
AT (1) ATE395338T1 (el)
AU (2) AU2005252183B2 (el)
BR (1) BRPI0511703B8 (el)
CA (1) CA2566945C (el)
CR (1) CR8766A (el)
CY (1) CY1108544T1 (el)
DE (1) DE602005006806D1 (el)
DK (1) DK1756064T3 (el)
EA (1) EA012431B1 (el)
EC (1) ECSP067062A (el)
ES (1) ES2306165T3 (el)
GE (1) GEP20094605B (el)
HR (1) HRP20080311T3 (el)
IL (1) IL179754A (el)
MA (1) MA28673B1 (el)
MX (1) MXPA06014084A (el)
MY (1) MY143599A (el)
NI (1) NI200600290A (el)
NO (1) NO339149B1 (el)
NZ (1) NZ551405A (el)
PE (1) PE20060427A1 (el)
PL (1) PL1756064T3 (el)
PT (1) PT1756064E (el)
SI (1) SI1756064T1 (el)
TN (1) TNSN06397A1 (el)
TW (1) TWI293952B (el)
UA (1) UA85884C2 (el)
WO (1) WO2005121097A2 (el)
ZA (1) ZA200609489B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
PL1756064T3 (pl) 2004-06-04 2008-11-28 Merck Sharp & Dohme Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania
JP2008507528A (ja) 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
JP2009502923A (ja) * 2005-07-26 2009-01-29 メルク エンド カムパニー インコーポレーテッド 置換ピラゾールを合成するための方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
KR20180099916A (ko) 2007-02-09 2018-09-05 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
GEP20135844B (en) 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound
ES2635767T3 (es) 2008-03-11 2017-10-04 Aska Pharmaceutical Co., Ltd. Dispersión sólida, composiciones farmacéuticas que contienen la misma, y procedimientos de producción de ambas
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP3153501B1 (en) 2008-08-13 2018-11-28 Metabasis Therapeutics, Inc. Glucagon antagonists
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
JP5562495B2 (ja) 2011-02-08 2014-07-30 ファイザー・インク グルカゴン受容体モジュレーター
KR20140023441A (ko) 2011-07-22 2014-02-26 화이자 인코포레이티드 퀴놀린일 글루카곤 수용체 조절제
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN109922831A (zh) 2016-08-30 2019-06-21 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271963A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
AU726311B2 (en) 1996-11-20 2000-11-02 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
AU730295B2 (en) 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
EP0945438B1 (en) * 1996-12-12 2003-03-05 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
KR20010006443A (ko) 1997-04-18 2001-01-26 쥐.디. 씨얼리 앤드 컴퍼니 심장혈관 질환 예방에의 시클로 옥시게나제-2 억제제 사용방법
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CN1282319A (zh) * 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
SI1042293T1 (sl) 1997-12-19 2008-08-31 Amgen Inc Substituirane piridinske in piridazinske spojine in njihova farmacevtska uporaba
TR200100773T2 (tr) 1998-09-17 2001-07-23 Bristol-Myers Squibb Company Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı diyabet tedavi yöntemi
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6624121B1 (en) * 1999-08-10 2003-09-23 Nihon Bayer Agrochem K.K. Herbicidal tetrazolinone derivatives
MXPA02004647A (es) * 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
TWI262917B (en) * 2002-02-01 2006-10-01 Dainippon Sumitomo Pharma Co 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
WO2004009158A2 (en) 2002-07-19 2004-01-29 Baxter International Inc. Systems and methods for performing peritoneal dialysis
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
AU2003298889A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
KR20050121732A (ko) * 2003-04-14 2005-12-27 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 당뇨병 치료를 위한ｎ-(((((1,3-티아졸-2-일)아미노)카르보닐)페닐)술포닐)페닐알라닌 유도체 및 관련 화합물
CN1784226A (zh) * 2003-05-09 2006-06-07 麦克公司 苯并咪唑化合物、含有苯并咪唑化合物的组合物以及使用方法
PL1756064T3 (pl) * 2004-06-04 2008-11-28 Merck Sharp & Dohme Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania
JP2008507528A (ja) * 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
AU2008229701B2 (en) 2010-03-04
UA85884C2 (uk) 2009-03-10
AU2008229701C1 (en) 2010-07-29
IL179754A0 (en) 2007-05-15
AU2008229701A1 (en) 2008-10-30
ECSP067062A (es) 2007-01-26
JP4108739B2 (ja) 2008-06-25
GEP20094605B (en) 2009-02-10
CA2566945A1 (en) 2005-12-22
AR088919A2 (es) 2014-07-16
NO339149B1 (no) 2016-11-14
JP4733153B2 (ja) 2011-07-27
PL1756064T3 (pl) 2008-11-28
JP2008505062A (ja) 2008-02-21
PT1756064E (pt) 2008-07-22
TWI293952B (en) 2008-03-01
JP2008150388A (ja) 2008-07-03
DE602005006806D1 (de) 2008-06-26
HRP20080311T3 (en) 2008-07-31
EA012431B1 (ru) 2009-10-30
EA200602196A1 (ru) 2007-06-29
AR049291A1 (es) 2006-07-12
MXPA06014084A (es) 2007-02-15
IL179754A (en) 2013-12-31
MA28673B1 (fr) 2007-06-01
ZA200609489B (en) 2007-10-31
BRPI0511703B1 (pt) 2018-07-17
PE20060427A1 (es) 2006-06-19
NO20070073L (no) 2007-03-05
TNSN06397A1 (en) 2008-02-22
AU2005252183B2 (en) 2008-07-17
NZ551405A (en) 2009-06-26
ATE395338T1 (de) 2008-05-15
NI200600290A (es) 2007-08-07
CA2566945C (en) 2010-09-21
BRPI0511703A (pt) 2008-01-08
US7799818B2 (en) 2010-09-21
ES2306165T3 (es) 2008-11-01
CR8766A (es) 2007-08-28
WO2005121097A3 (en) 2006-02-16
TW200604179A (en) 2006-02-01
BRPI0511703B8 (pt) 2021-05-25
CN1964947A (zh) 2007-05-16
US20050272794A1 (en) 2005-12-08
US7598285B2 (en) 2009-10-06
EP1756064B1 (en) 2008-05-14
AU2005252183A1 (en) 2005-12-22
DK1756064T3 (da) 2008-09-22
US20090176854A1 (en) 2009-07-09
WO2005121097A2 (en) 2005-12-22
EP1756064A2 (en) 2007-02-28
SI1756064T1 (sl) 2008-12-31
MY143599A (en) 2011-06-15

Similar Documents

Publication Publication Date Title
CY1108544T1 (el) Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης
CY1117027T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
CY1112946T1 (el) 4-υδροξυβενζομορφανια
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
ATE365703T1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate,deren herstellung und anwendungen
ATE433961T1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
ATE507246T1 (de) Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel
CY1115441T1 (el) Αναστολεις p38 και μεθοδοι χρησης αυτων
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
EP1765335A4 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
UY28348A1 (es) Compuestos novedosos
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
DK1543063T3 (da) Medikament levering
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
ATE489382T1 (de) Benzoxazinonderivate, deren herstellung und verwendung als arzneimittel
ATE401875T1 (de) Pharmazeutische feste dispersionen von modafinil- verbindungen
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.